The same set of clinical data on Cabometyx and Tecentriq in prostate cancer has led to two distinct regulatory plans between ...

Sandoz and United Therapeutics’ years-long dispute over a generic to pulmonary arterial hypertension med treprostinil has ...

PhRMA is pushing the FDA to expand drug manufacturers’ powers to correct misinformation about their products, i | PhRMA is ...

Palisade Bio is fortifying its brand image. The California-based biotech on Monday unveiled a new logo and website design, ...

Three years after establishing an immunology unit, Eli Lilly has gained its third FDA approval in the specialty area as the U ...

Almirall has rolled out a new campaign for World Atopic Eczema Day, kicking off its “The T | Almirall has rolled out a new ...

Following a meeting with the FDA’s Gastrointestinal Drug Advisory Committee Friday, the future of Intercept’s rare liver ...

We’re finally moving towards a causality-based nosology for psychiatry: specific symptoms with defined biological ...

Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign out ...

Bayer is targeting a broader use of Nubeqa in metastatic hormone-sensitive prostate (mHSPC) cancer with a combination free of ...

AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...